Honeywell (HON) stock rose 1.7% in December 2016. The company’s stock performance in December was muted compared to November’s returns of 3.9%.
On January 6, 2017, Axalta (AXTA) announced that it had acquired Ellis Paint Company. Axalta didn’t disclose the financial terms of the deal.
On January 5, 2017, PPG Industries (PPG) announced that it had completed the acquisition of DEUTEK, a leading Romanian paint and architectural coatings manufacturer.
On January 4, 2017, Albemarle (ALB) announced that it had issued a tender offer to repurchase debt worth $500 million.
Short interest as a percentage of shares outstanding in TC PipeLines (TCP) stock for the settlement date of December 15, 2016, was 0.3%.
As of January 4, 2017, Dow Chemical (DOW) was trading at a one-year forward PE multiple of 14.3x.
As of January 4, 2017, 20 brokerage firms were actively tracking Dow Chemical stock. Of these analysts, 75.0% have recommended a “buy” for the stock.
The Fed’s rate hike in December 2016 is expected to benefit DOW’s pension plan in fiscal 2017 because a higher discount rate will be applied to calculate PBO.
Dow Chemical (DOW) stock continued its upward trend in December, rising 2.7% after a 3.6% rise in November.
In a survey based on the recommendations of 17 brokerage companies, BDX was given “buy” ratings by ~65% of analysts. About 29% issued “hold” recommendations, and ~6% issued “sell” recommendations on the stock.
On December 29, 2016, BDX stock was trading 28.3% above its 52-week low of $129.50 on February 9, 2016, and 5% below its 52-week high of $181.70 on September 22, 2016.
Becton, Dickinson and Company (BDX), expects its 2017 sales to be hit due to the divestiture of its Respiratory Solutions business, which was completed in October 2016.
BDX expects to generate operating cash flows of more than $11 billion for the five-year period from 2016 to 2019.
The BD Medical business generated revenues of ~$8.7 billion in fiscal 2016, which ended September 30, 2016.
Becton, Dickinson and Company (BDX) generates ~$1 billion from its Infection Prevention business.
BDX’s R&D investments totaled ~$828 million in fiscal 2016, which represents an annual growth of ~31%.
BDX’s Lifesciences business generated revenues of ~$3.8 billion in fiscal 2016, ended September 30, 2016.
Becton, Dickinson and Company (BDX) recently launched BD Barricor and BD Ultra Touch Push Button under its Pre-Analytical Systems division.
After executing its growth strategies during the last five years, Becton, Dickinson and Company (BDX) has achieved its targeted growth rates of 5% top-line organic growth and 10% bottom-line growth.
St. Jude Medical (STJ) announced a fiscal 4Q16 cash dividend of $0.31 per share on December 9, 2016.